Healthcare shares are mixed in pre-market trade.
Health and well-being company UnitedHealth Group Inc. (
) is down more than 2% this morning after it reported Q4 diluted
EPS of $1.41, a penny better than the analyst consensus on Capital
IQ. Revenues for the period totaled $31.1 billion, up from $28.8
billion last year and in line with expectations.
The company continues to estimate 2014 revenues of $128 billion
to $129 billion and net earnings in the range of $5.40 to $5.60 per
share. The Street is at $131.9 bln in revenue and earnings of $5.62
UNH is up 4.2% at $78 apiece in the pre-market session.
And, Life science tools maker Illumina Inc. (
) has entered into an agreement with Amgen Inc. (
) to develop and commercialize a multigene, NGS-based test as a
companion diagnostic for Vectibix for the treatment of metastatic
Vectibix has been approved in the U.S. and EU. Under the terms
of the collaboration, the companies will seek premarket approval of
the test by the US Food and Drug Administration (FDA) and other
regulatory bodies. The test will be developed for use with
Illumina's MiSeqDx instrument, which received premarket clearance
from the FDA and was CE-marked for the European Union in 2013.
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.